Abstract
KILLED Corynebacterium parvum has been effective when administered into tumours or when included as a subcutaneous inoculum containing tumour cells (the subcutaneous site, unlike the intradermal site1, facilitates early tumour cell dissemination)2–4. After tumour rejection, the augmented host resistance prevented progressive growth of potentially lethal metastases present at the time of therapy5. In addition, animals rejecting tumours formed from primary grafts of tumour cells admixed with killed C. parvum (compared with those rejecting tumours after intratumour therapy with C. parvum) exhibited an augmented tumour-specific protection against inoculation of large challenge cell doses6. Whitmire and Huebner7 reported a significant decrease in incidence of 3-methyl-cholanthrene-induced malignancies in C57BL/Cum and BALB/c Cv mice after preimmunisation with formalin-killed wild-type virus and Rauscher leukaemia virus vaccines administered with Freund's complete adjuvant. We have now found a considerable decrease in the incidence of spontaneous tumours in the high-incidence strain of DBA/2 mice after rejection of tumours formed from subcutaneous transplants of syngeneic mammary adenocarcinoma cells admixed with killed C. parvum.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
